Compare ANL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANL | NEPH |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 60.0M |
| IPO Year | 2023 | 2004 |
| Metric | ANL | NEPH |
|---|---|---|
| Price | $1.42 | $5.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 31.4K | ★ 67.7K |
| Earning Date | 04-20-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $17,930,000.00 |
| Revenue This Year | N/A | $33.32 |
| Revenue Next Year | N/A | $12.27 |
| P/E Ratio | ★ N/A | $36.23 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $0.88 | $1.39 |
| 52 Week High | $2.99 | $6.42 |
| Indicator | ANL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 49.99 |
| Support Level | $1.42 | $4.80 |
| Resistance Level | $1.70 | $5.97 |
| Average True Range (ATR) | 0.18 | 0.42 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 65.39 | 42.04 |
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.